AH Bio Fund II, L.P. bought SCTX
July 27, 2026 · Form 4 insider transaction
AH Bio Fund II, L.P. bought 333,333 shares of Scribe Therapeutics Inc. at $15.00 per share, a transaction worth $5.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.